On April 29th the U.S. Food and Drug Administration (FDA) approved Nuplazid (pimavanserin) tablets, the first drug officially authorized to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.
Hallucinations or delusions can occur in as many as 50 percent of patients with Parkinson’s disease at some time during the course of their illness. People who experience them see or hear things that are not there (hallucinations) and/or have false beliefs (delusions). The hallucinations and delusions experienced with Parkinson’s disease are serious symptoms, and can lead to thinking and emotions that are so impaired that the people experiencing them may not relate to loved ones well or take appropriate care of themselves.
FDA Approves Nuplazid For Treatment Of PD Psychosis
Read the full article here.
Nuplazid™ is marketed by Acadia Pharmaceuticals Inc. of San Diego, CA.
The NeuroCommunity Foundation maintains a contact list of people who are interested in participating in clinical trials and research studies at local sites and online. You do not need to have Parkinson’s disease to volunteer, a lot of studies need control groups as well as patients. If you would like to make a difference and help to find better treatments and ultimately a cure, please contact us here and write “research contact list” in the subject line. If you are hesitating or need more information about a specific study, we can put you in contact with someone who has personal experience.
We continuously update the available opportunities and post results and FDA approvals as they come in. We also welcome your feedback and suggestions about your participation in studies. You can email us or speak you mind in the comments box below.
The NeuroCommunity Foundation is here for you:
For information about Parkinson’s disease and other movement disorders, support groups, wellness programs, education events, and local resources in northern Los Angeles county, Ventura county, Central Coast & Central Valley, contact us here or call 818-885-8623 to speak with Viviane Tondeur, Education Director, Parkinson & Movement Disorder Information Center, The NeuroCommunity Foundation.
Leave a Reply